Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 3 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Pricing and Reimbursement in China - Introduction | 8 | 1 |
| Healthcare System in China - Overview | 9 | 22 |
| Introduction | 9 | 1 |
| Sizable Population and Increase in Life Expectancy | 10 | 2 |
| Socio-Economic and Demographic Trends Affecting the Healthcare Sector | 12 | 1 |
| Shift in Demographics | 12 | 1 |
| Rise in Personal Disposable Income | 13 | 1 |
| Rise in Lifestyle Diseases | 14 | 1 |
| Healthcare Expenditure | 15 | 3 |
| Healthcare Expenditure Comparatively Low | 18 | 1 |
| Healthcare System in China: A Backdrop | 19 | 1 |
| Wide Gap between Need for Healthcare Services and Health Insurance and Delivery System | 19 | 1 |
| Limitations of BHIS | 19 | 1 |
| Wide Disparity in Rural and Urban Healthcare Systems | 20 | 1 |
| PEST Analysis | 21 | 1 |
| Political Factors | 22 | 1 |
| Economic Factors | 22 | 1 |
| Social Factors | 22 | 1 |
| Technological Factors | 22 | 1 |
| Healthcare Regulation | 23 | 2 |
| Ministry of Health | 25 | 1 |
| Provincial Department of Health | 25 | 1 |
| City Department of Health | 25 | 1 |
| Township Department of Health | 25 | 1 |
| Village Health Administration | 25 | 1 |
| The National Development and Reform Commission (NDRC) | 25 | 1 |
| Chinese Center for Disease Control and Prevention (China CDC) | 25 | 1 |
| The Ministry of Finance (MoF) | 25 | 1 |
| Ministry of Labor and Social Security (MoLSS) | 26 | 1 |
| Healthcare Reforms 2009 Aimed to Offer Better Access, Efficiency and Quality | 26 | 1 |
| Basic Level Healthcare Services | 27 | 1 |
| Basic Healthcare Insurance System | 27 | 1 |
| Essential Medicine System to Offer Twin Benefits: Curb Rising Drug Prices and Easy Accessibility of Drugs | 27 | 1 |
| Cut in Markup in Drug Sales to Hard Hit Public Health Facilities | 28 | 1 |
| Equitable Public Health Service &Public Hospital Reform | 28 | 1 |
| Effectiveness of Healthcare Reform 2009 | 29 | 1 |
| Improved Basic Medical Insurance System | 30 | 1 |
| Evolving Trends in the Healthcare System in China | 30 | 1 |
| Increase in Taiwanese Investment in Hospitals in China | 30 | 1 |
| Hospital Advertising | 30 | 1 |
| Pricing and Reimbursement in China - Overview | 31 | 4 |
| Pharmaceuticals in Healthcare Systems in China | 31 | 2 |
| OTC Drug Market in China | 33 | 2 |
| Pricing and Reimbursement in China - Pricing | 35 | 14 |
| Drug Pricing Mechanism | 35 | 1 |
| Pricing of List A Drugs | 36 | 1 |
| Pricing of List B Drugs | 36 | 1 |
| Principles for Government Pricing: | 37 | 1 |
| NDRC Drug Pricing: Criteria for Evaluation | 37 | 1 |
| Objectives for Drug Price Regulation in China | 38 | 1 |
| National Essential Medicines List (NEML) | 39 | 1 |
| National Essential Medicines List - 2009 | 39 | 2 |
| Essential Drugs List (2000 - 2009) | 41 | 1 |
| NEML 2009 Continues to Focus on Affordability and Accessibility | 42 | 1 |
| Drug Regulation Pattern | 42 | 1 |
| Key Reasons for High Drug Price in China | 42 | 1 |
| Differential Drug Pricing | 42 | 1 |
| Pricing Premiums | 43 | 1 |
| Foreign Drugs Exempt from Price Cuts | 43 | 1 |
| Drug Pricing Trends Closely Followed by R&D-Based Pharmaceutical Companies | 43 | 1 |
| Drug Registration Process | 44 | 1 |
| Classification of Drugs | 44 | 1 |
| New Drug Applications | 44 | 1 |
| Abbreviated New Drug Applications | 45 | 1 |
| Registration Supplements | 45 | 1 |
| License Renewal | 45 | 1 |
| New Drug Registration Process: | 45 | 1 |
| Negative Pricing Pressures Not Effective in Stemming Healthcare Expenditures | 46 | 2 |
| Challenges Facing Pricing and Reimbursement in China | 48 | 1 |
| Pricing and Reimbursement in China - Reimbursement Scenario | 49 | 9 |
| Health Insurance in China | 49 | 1 |
| Urban Health Insurance | 50 | 1 |
| Rural Health Insurance | 50 | 1 |
| Private Insurance | 50 | 1 |
| Private Insurance Sector is Thriving | 51 | 1 |
| Universal Health Insurance Coverage | 52 | 1 |
| Drug Reimbursement in China | 53 | 2 |
| NDRL Listing Implications | 55 | 1 |
| Role of Key Stakeholders in Approving Drugs for Reimbursement | 55 | 1 |
| Key Criteria for the Drug Reimbursement Selection Process | 55 | 2 |
| NDRL 2009 to Push Drug Sales in the Future | 57 | 1 |
| Mixed Implications of being Listed on NEML | 57 | 1 |
| Appendix | 58 | 5 |
| Market Definitions | 58 | 1 |
| Abbreviations | 58 | 2 |
| Sources | 60 | 1 |
| Research Methodology | 60 | 2 |
| Healthcare System | 60 | 1 |
| Methodology | 60 | 1 |
| Sources of Coverage | 60 | 1 |
| Pharmaceutical Regulations | 61 | 1 |
| Methodology | 61 | 1 |
| Sources of Coverage | 61 | 1 |
| Pricing of Pharmaceutical Drugs | 61 | 1 |
| Methodology | 61 | 1 |
| Sources of Coverage | 61 | 1 |
| Reimbursement of Pharmaceutical Drugs | 61 | 1 |
| Methodology | 61 | 1 |
| Sources of Coverage | 61 | 1 |
| Pricing and Reimbursement in Major Therapy Areas | 61 | 1 |
| Methodology | 61 | 1 |
| Sources of Coverage | 61 | 1 |
| Contact Us | 61 | 1 |
| Disclaimer | 62 | 1 |